Multiple sclerosis relapsing remitting. Medical search. Frequent questions

To investigate the pattern of cognitive impairment in relapsing remitting multiple sclerosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients using a computerized battery. (hindawi.com)
Cognitive impairment has been demonstrated at all stages and in all subtypes of the disease: clinically isolated syndrome (CIS), relapsing remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), and even benign multiple sclerosis [ 11 ]. (hindawi.com)
A 37-year-old woman with relapsing-remitting multiple sclerosis (RRMS) presents with new-onset blurred vision and unilateral periocular pain. (medscape.com)
Skill Checkup: Suboptimally Treated Relapsing-Remitting Multiple Sclerosis (RRMS) - Medscape - Jan 26, 2022. (medscape.com)
OBJECTIVE: To assess changes in RS-FC in early relapsing-remitting MS (RRMS) patients associated with repetitive thumb flexions (RTFs). (cardiff.ac.uk)
There is little information on this phenomenon among patients with relapsing-remitting multiple sclerosis (RRMS), one of the most common causes of disability and loss of autonomy in young adults. (gencat.cat)
In the present study, mean serum UA levels were lower in RRMS and relapse patients with MS than in the other neurological diseases (OND) group, but the difference did not reach significance level. (ejgm.org)
Relapsing-remitting multiple sclerosis (RRMS) is a chronic immune-mediated inflammatory disease characterized by central nervous system (CNS) demyelination and axonal damage. (mun.ca)
Autologous hematopoietic stem cell treatment (AHSCT) is considered an effective treatment option for patients with aggressive relapsing-remitting multiple sclerosis (RRMS). (ku.dk)
Background and purpose Dimethyl fumarate (DMF) causes a mean lymphocyte count drop of approximately 30% in relapsing-remitting multiple sclerosis (RRMS) patients. (univaq.it)
Background: Simultaneous comparisons of multiple disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) over an extended follow-up are lacking. (unipr.it)
Our study demonstrated that myelin volume fraction (MVF) and myelin volume (MyV) obtained by a multi-parametric quantitative synthetic MRI might be useful for evaluating gray matter (GM) myelin alterations and for monitoring disease progression in relapsing-remitting multiple sclerosis (RRMS) patients. (ismrm.org)
The investigators present the pathological findings in 12 patients with RRMS who tragically died during or shortly after the onset of a relapse. (ms-selfie.blog)

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing-remitting multiple sclerosis in adults. (nice.org.uk)
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. (unich.it)

The functional consequences of cognitive impairment in multiple sclerosis (MS) patients can be devastating. (hindawi.com)
In conclusion, preclinical studies show that laquinimod's unique mechanisms of action, including its immunomodulatory and CNS-protective effects, translate into clinical benefits in relapsing-remitting multiple sclerosis patients. (nih.gov)
Long-term treatment of relapsing-remitting multiple sclerosis with interferon β: how strongly should we encourage patients to adhere to the 'old' therapies? (bmj.com)
We aimed to investigate the evolution of different MRI measures in early relapsing-remitting patients with MS and in normal controls (NCs) over 2 years. (bmj.com)
As a group, multiple sclerosis patients demonstrated significant negative correlations between disease duration and glutamate or GABA (ρ = -0.4, p = 0.02) but not glutamine or glutathione. (lu.se)
Alone, only relapsing-remitting multiple sclerosis patients exhibited a significant negative correlation between disease duration and GABA (ρ = -0.5, p = 0.03). (lu.se)
Background: Interferon beta (IFNB) is available in parenteral formulations for treatment of multiple sclerosis (MS). The purpose of this study was to evaluate safety, tolerability and effects on MRI lesions of three different doses of oral IFNB-1a compared with placebo over six months in relapsing-remitting (RR) MS patients. (amsterdamumc.org)
Approximately two-thirds of patients in each group remained relapse free. (amsterdamumc.org)
METHODS: Using MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. (unich.it)
We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients with relapsing-remitting multiple sclerosis. (qxmd.com)
Patients with relapsing-remitting multiple sclerosis (age 18-65 years, with Expanded Disability Status Scale score ≤5) were randomly assigned (1:1:1) via an interactive voice response or web system, and stratified by site, to placebo or subcutaneous peginterferon beta-1a 125 μg once every 2 weeks or every 4 weeks. (qxmd.com)
417 (83%) patients taking placebo, 481 (94%) patients taking peginterferon every 2 weeks, and 472 (94%) patients taking peginterferon every 4 weeks reported adverse events including relapses. (qxmd.com)
Heidi Crayton, MD, provides an update on the oral management considerations in patients with relapsing remitting multiple sclerosis. (neurologylive.com)
Heidi Crayton, MD, shares her thoughts surrounding treatment initiation and management considerations in patients with relapsing-remitting multiple sclerosis. (neurologylive.com)
Dr Heidi Crayton reviews treatment efficacy and safety considerations for conventional and novel treatment options for patients with relapsing-remitting multiple sclerosis. (neurologylive.com)
An expert in neurology provides insight into the considerations of oral versus injectable therapies in patients with multiple sclerosis, highlighting their impact on quality of life, brain volume, and cognitive health. (neurologylive.com)
Heidi Crayton, MD, comments on cognitive and brain health considerations in patients with multiple sclerosis and shares her experiences with both patients and their caregivers. (neurologylive.com)
Dr Heidi Crayton reviews the potential impact of vaccinations on immunosuppressive disease-modifying therapy efficacy in patients with multiple sclerosis. (neurologylive.com)
Heidi Crayton, MD, expresses her optimism for the future of multiple sclerosis and highlights emerging therapies and their impact on the care of patients with multiple sclerosis. (neurologylive.com)
Method: Nationwide retrospective single center study of patients with multiple sclerosis (MS) treated with AHSCT. (ku.dk)
Regional distribution and evolution of gray matter damage in different populations of multiple sclerosis patients. (crossref.org)
To test the hypothesis that immunotherapy prevents long-term disability in relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 patients. (msbase.org)
During the treated periods, patients were less likely to experience relapses (hazard ratio 0.60, 95% confidence interval [CI] 0.43-0.82, p = 0.0016), worsening of disability (0.56, 0.38-0.82, p = 0.0026), and progress to EDSS step 6 (0.33, 0.19-0.59, p = 0.00019). (msbase.org)
Among 1,085 patients with ≥15-year follow-up, the treated patients were less likely to experience relapses (0.59, 0.50-0.70, p = 10 -9 ) and worsening of disability (0.81, 0.67-0.99, p = 0.043). (msbase.org)
The outcome of interest was the proportion of relapse -free patients in 2 years. (bvsalud.org)
The aim of this work was to investigate the serum level of BDNF in patients with relapsing-remitting multiple sclerosis and the relation between BDNF and disease activity and severity. (springeropen.com)
A case-control study was conducted on 90 subjects: 60 patients with relapsing-remitting multiple sclerosis (30 in relapse and 30 in remission) on different lines of medical treatment and 30 healthy volunteers as a control. (springeropen.com)
The BDNF level was significantly higher in MS patients in relapse than in patients in remission ( P value = 0.006). (springeropen.com)
In the remission group, there was no significant linear correlation between different MS patients' characteristics and BDNF level, while in the relapse group, a positive linear correlation was found between the number of T2 infratentorial lesions and BDNF level ( r = 0.402, P = 0.028). (springeropen.com)
BDNF was significantly higher in relapsing-remitting multiple sclerosis patients in the relapse phase. (springeropen.com)
Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system, destroying the myelin and the axon in variable degrees and producing significant physical disability within 20-25 years in more than 30% of patients. (medscape.com)
A routine brain MR imaging should be considered every 6 months to 2 years for all patients with relapsing MS. (medscape.com)

Recent findings from the clinical trials indicate that laquinimod has significant effects in reducing relapse rate and has more pronounced effects in reducing sustained disability progression as well as brain atrophy, with a good safety profile. (nih.gov)
INTERPRETATION: This study suggests that in active multiple sclerosis during treatment with injectable disease-modifying therapies, switching to natalizumab is more effective than switching to fingolimod in reducing relapse rate and short-term disability burden. (unich.it)

T cell responses after hematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. (stembook.org)

The course of symptoms occurs in two main patterns initially: either as episodes of sudden worsening that last a few days to months (called relapses, exacerbations, bouts, attacks, or flare-ups) followed by improvement (85% of cases) or as a gradual worsening over time without periods of recovery (10-15% of cases). (wikipedia.org)
The 2011 AAN guideline for plasmapheresis in neurological diseases categorizes plasmapheresis as "probably effective" as second-line treatment for relapsing MS exacerbations that do not respond to steroids. (medscape.com)

The pathophysiology of progressive multiple sclerosis remains elusive, significantly limiting available disease-modifying therapies. (lu.se)
Children and teens with multiple sclerosis are treated with the same therapies as adults, but they are considered "off label" for treating children, (not an FDA approved the use of the drug, but it is/may be effective for some people with the condition). (medicinenet.com)
With the advent of newer disease-modifying therapies (DMTs), treatment goals are to reduce relapse frequency and MRI disease activity, and ultimately limit progression of disability . (medscape.com)
This study provides evidence that disease-modifying therapies are effective in improving disability outcomes in relapsing-remitting MS over the long term. (msbase.org)
Compared with glatiramer acetate (reference), several therapies showed a superior ATE in reducing relapses: natalizumab (HR=0.44, 95% CI=0.40 to 0.50), fingolimod (HR=0.60, 95% CI=0.54 to 0.66) and dimethyl fumarate (HR=0.78, 95% CI=0.66 to 0.92). (unipr.it)
Treatment of multiple sclerosis (MS) has 2 aspects: immunomodulatory therapy (IMT) for the underlying immune disorder and therapies to relieve or modify symptoms. (medscape.com)

People may wish to consider both the significant benefits and adverse effects caused by newer medications, such as fingolimod (Gilenya), natalizumab (Tysabri), and alemtuzumab (Lemtrada) for treating their Multiple Sclerosis. (medicalnewstoday.com)

Multiple sclerosis is a disease that involves an immune-mediated process that results in an abnormal response in the body's immune system that damages central nervous system (CNS) tissues in which the immune system attacks myelin, the substance that surrounds and insulates nerve fibers causing demyelination that leads to nerve damage. (medicinenet.com)
In multiple sclerosis, patches of myelin (the substance that covers most nerve fibers) and underlying nerve fibers in the brain, optic nerves, and spinal cord are damaged or destroyed. (msdmanuals.com)

Marginal structural models were used to compare the cumulative hazards of 12-month confirmed increase and decrease in disability, Expanded Disability Status Scale (EDSS) step 6, and the incidence of relapses between treated and untreated periods. (msbase.org)
The outcomes analysed were incidence of relapses, 12-month confirmed disability worsening and improvement. (unipr.it)

A recent Cochrane systematic review demonstrated that intramuscular interferon beta 1a (IFN-ß-1a-IM) was inferior to the other beta interferons (IFN-ßs) for multiple sclerosis (MS). As a result, CONITEC commissioned an analysis to review possible disinvestment within SUS. (bvsalud.org)

Methods: In this study, we aimed to investigate serum UA levels in relapsing-remitting (RR) MS. In addition we compared serum UA levels by means of clinical activity, expanded disability status scale (EDSS) and disease duration. (ejgm.org)
As the primary outcome, we will address disability as defined by the Expanded Disability Status Scale or multiple sclerosis functional composite scores followed by relapse frequency, quality of life measures, and side effects. (gencat.cat)

Laquinimod is a novel, small, orally administered medication that has demonstrated efficacy in the treatment of multiple sclerosis, a chronic inflammatory demyelinating disease of the CNS. (nih.gov)

The annualized relapse rates decreased from 1.5 to 0.2 on natalizumab and from 1.3 to 0.4 on fingolimod, with 50% relative postswitch difference in relapse hazard (p? (unich.it)
The pairwise ATT comparisons also showed superior effects of natalizumab followed by fingolimod on relapses and disability. (unipr.it)

NEDA-3 is defined as absence of clinical relapses, MRI disease activity and confirmed disability progression. (univaq.it)

Under current guidelines, a multiple sclerosis (MS) diagnosis most often occurs over the course of months and requires clinical assessment, magnetic resonance imaging (MRI), and a lumbar puncture. (mun.ca)
[ 1 ] Magnetic resonance imaging (MRI) of the brain is useful in the diagnosis and treatment of multiple sclerosis . (medscape.com)
Usually, doctors diagnose multiple sclerosis based on symptoms and results of a physical examination and magnetic resonance imaging. (msdmanuals.com)

MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). (wikipedia.org)
In the relapsing forms of MS, between attacks, symptoms may disappear completely, although some permanent neurological problems often remain, especially as the disease advances. (wikipedia.org)
Thiamine deficiency or lack of activity causes neurological manifestations, especially symptoms of depression, intrinsic to multiple sclerosis (MS) and related to its pathogenesis. (mdpi.com)
It also examines how to manage symptoms and relapses. (medicalnewstoday.com)
In most people with multiple sclerosis, periods of relatively good health alternate with episodes of worsening symptoms, but over time, multiple sclerosis gradually worsens. (msdmanuals.com)
Most people with multiple sclerosis have periods of relatively good health (remissions) alternating with periods of worsening symptoms (flare-ups or relapses). (msdmanuals.com)

Mean age at baseline was 30.7 years, mean disease duration was 5.5 years, mean EDSS was 1.8 and mean annualised relapse rate before study entry was 1.7. (bmj.com)
UA levels did not correlate with clinical activity, EDSS score and disease duration either in relapse or remitting or both of them. (ejgm.org)

On thoracic vertebral MRI examination without contrast and brain MRI with contrast obtained multiple sclerosis lesions. (upnvj.ac.id)
Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H.: Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. (crossref.org)
An automated tool for detection of flair-hyperintense white-matter lesions in multiple sclerosis. (crossref.org)
The name "multiple sclerosis" is short for multiple cerebro-spinal sclerosis, which refers to the numerous glial scars (or sclerae - essentially plaques or lesions) that develop on the white matter of the brain and spinal cord. (wikipedia.org)
Coronal fluid-attenuated inversion recovery (FLAIR) MRI in a patient with multiple sclerosis demonstrates periventricular high-signal intensity lesions, which exhibit a typical distribution for multiple sclerosis. (medscape.com)
Axial diffusion-weighted MRI in a patient with multiple sclerosis shows several hyperintense lesions, a feature of inflammatory disease activity. (medscape.com)
In addition, depending on the number and location of findings, MRI can vary greatly in terms of sensitivity and specificity in the diagnosis of MS. This is especially true of primary progressive MS, which may not show the classic discrete lesions of relapsing-remitting MS. (medscape.com)
Plain radiographic studies have no positive predictive value in the diagnosis of multiple sclerosis, but occasionally, plain radiographs may be used to exclude mechanical bony lesions. (medscape.com)

In the whole cohort, relapse-free survival (RFS) was 77% (95% CI: 64-94%), worsening-free survival (WFS) was 79% (95% CI: 66-96%), MRI event-free survival (MFS) was 93% (95% CI: 85-100%), and no evidence of disease (NEDA-3) was 69% (95% CI: 54-89%) at the end of year two post-AHSCT. (ku.dk)
Eriksson I, Cars T, Piehl F, Malmström R, Wettermark B, von Euler M. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population based cohort study. (janusinfo.se)

Huang, W.J., Chen, W.W., Zhang, X.: Multiple sclerosis: pathology, diagnosis and treatments. (crossref.org)
Geurts, J.J., Calabrese, M., Fisher, E., Rudick, R.A.: Measurement and clinical effect of grey matter pathology in multiple sclerosis. (crossref.org)
In vivo characterization of cortical and white matter neuroaxonal pathology in early multiple sclerosis. (crossref.org)
The chronic inflammation in multiple sclerosis pathology contradicts immune mechanisms that modulate and confine the inflammatory cascade to limit irreversible demyelination and axonal damage [ 2 ]. (springeropen.com)

Relapse and disability outcomes were compared in paired, pairwise-censored analyses. (unich.it)

3] Dobson R, Giovannoni G. Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. (upnvj.ac.id)

Cochrane Abstracts , Evidence Central , evidence.unboundmedicine.com/evidence/view/Cochrane/438161/all/Rituximab_for_relapsing_remitting_multiple_sclerosis:_Cochrane_systematic_review. (unboundmedicine.com)

better outcomes are more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. (wikipedia.org)

After 48 weeks, peginterferon beta-1a significantly reduced relapse rate compared with placebo. (qxmd.com)

Conclusion: We describe a clinically applicable cell therapeutic approach for controlling relapses in autoimmune encephalomyelitis by specifically silencing the deleterious autoimmune response. (uni-koeln.de)
The primary objective of this review is to assess the differential treatment effects of all approved DMTs in subgroups of adults with clinically isolated syndrome or relapsing forms of MS. We will analyse possible treatment effect modifiers (TEM) defined by baseline demographic characteristics (gender, age), and diagnostic (i.e. (gencat.cat)

Marginal structural Cox models (MSMs) were used to estimate the average treatment effects (ATEs) and the average treatment effects among the treated (ATT), rebalancing the compared groups at 6-monthly intervals on age, sex, birth-year, pregnancy status, treatment, relapses, disease duration, disability and disease course. (unipr.it)

Continued treatment with MS immunotherapies reduces disability accrual by 19%-44% (95% CI 1%-62%), the risk of need of a walking aid by 67% (95% CI 41%-81%), and the frequency of relapses by 40-41% (95% CI 18%-57%) over 15 years. (msbase.org)
IMT is directed toward reducing the frequency of relapses and slowing progression. (medscape.com)

Background: Dendritic cells (DCs) rendered suppressive by treatment with mitomycin C and loaded with the autoantigen myelin basic protein demonstrated earlier their ability to prevent experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis (MS). This provides an approach for prophylactic vaccination against autoimmune diseases. (uni-koeln.de)
Methods: We replaced DCs by peripheral mononuclear cells and myelin autoantigens by glatiramer acetate (Copaxone (R)), a drug approved for the treatment of MS. Spleen cells were loaded with Copaxone (R), incubated with mitomycin C (MICCop) and injected into mice after the first bout of relapsing-remitting EAE. (uni-koeln.de)
Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. (qxmd.com)
The drug might be an effective treatment for relapsing-remitting multiple sclerosis with less frequent administration than available treatments. (qxmd.com)
15] Garg N, Weinstock-Guttman B. Treatment of pain, paresthesias and paroxysmal disorders in multiple sclerosis. (upnvj.ac.id)
It's normal to worry about the cost of multiple sclerosis (MS) treatment. (webmd.com)
Is Stem Cell Therapy Safe for Relapsing-Remitting Multiple Sclerosis Treatment? (medindia.net)
Acyclovir treatment of relapsing-remitting multiple sclerosis. (msdiscovery.org)
The real-world assessment further demonstrated that IFN-ß-1a-IM users had a statistically higher risk of treatment failure , defined as treatment switching or relapse treatment or death , with the assessment showing that IFN-ß-1a-IM was inferior to the other IFN-ßs and to glatiramer acetate in both direct and indirect analysis . (bvsalud.org)
Currently, most disease-modifying agents have been approved for use only in relapsing forms of MS. Mitoxantrone (see below) is also approved for the treatment of secondary (long-term) progressive and progressive relapsing MS. (medscape.com)
Decisions regarding early treatment of relapsing MS can be guided by using the McDonald diagnostic criteria. (medscape.com)

Multiple sclerosis is one of the most common neurological disorders in young adults. (springeropen.com)
Because of the neurotropism of Lyme disease, speculative websites and articles and even peer-reviewed journals have purported causal associations between Lyme disease and several neurodegenerative disorders, including Alzheimer disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson disease ( 6 - 11 ). (cdc.gov)

In preclinical testing, laquinimod inhibited the development of both acute and chronic paralysis in the multiple sclerosis model, experimental autoimmune encephalomyelitis. (nih.gov)
Multiple Sclerosis Journal - Experimental, Translational and Clinical. (upnvj.ac.id)
Characterizing microstructural tissue properties in multiple sclerosis with diffusion MRI at 7 T and 3 T: the impact of the experimental design. (crossref.org)

Because the exact antigen or target of the immune-mediated attack is not known, many experts prefer to label multiple sclerosis as 'immune-mediated instead of an autoimmune disease. (medicinenet.com)

Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system (CNS) and often causes significant physical disability over time. (medscape.com)
Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. (wikipedia.org)

There is growing evidence for the concept of multiple sclerosis (MS) as an inflammatory neurodegenerative disease, with a different pattern of atrophy evolution in grey matter (GM) and white matter (WM) tissue compartments. (bmj.com)
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS) , which includes the brain , spinal cord , and optic nerve . (healthline.com)
Aim: Multiple sclerosis (MS) is an inflammatory demyelinating disease with unknown origin. (ejgm.org)
Background Multiple sclerosis (MS) is an inflammatory and degenerative disease of the central nervous system with an increasing worldwide prevalence. (gencat.cat)

Progression of regional grey matter atrophy in multiple sclerosis. (crossref.org)

Can children and teenagers develop multiple sclerosis (pediatric MS)? (medicinenet.com)

Fast Five Quiz: Managing Progression of Relapsing-Remitting Multiple Sclerosis - Medscape - Jul 01, 2022. (medscape.com)

Results: MICCop cells were able to inhibit the harmful autoreactive T-cell response and prevented mice from further relapses without affecting general immune responses. (uni-koeln.de)

We employed, at 7 T, a previously validated 1 H-MRS protocol to measure glutamate, GABA, and glutathione, as well as glutamine, N-acetyl aspartate, choline, and myoinositol, in the frontal cortex of individuals with relapsing-remitting (N = 26) or progressive (N = 21) multiple sclerosis or healthy control adults (N = 25) in a cross-sectional analysis. (lu.se)

This study demonstrates the utility of MSM in emulating trials to compare clinical effectiveness among multiple interventions simultaneously. (unipr.it)

The National Multiple Sclerosis Society estimates that more than 2.3 million people worldwide have MS. That includes an estimated 1 million people in the United States , according to a 2017 study by the Society. (healthline.com)
An older 2017 study explains that although newer multiple sclerosis medications are more effective, they can have more serious side effects. (medicalnewstoday.com)

Multiple sclerosis ( MS ) is a disease that causes demyelination (disruption of the myelin that insulates and protects nerve cells) of spinal nerve and brain cells. (medicinenet.com)
Multiple sclerosis is a disease that causes demyelination of the brain and spinal cord nerve cells. (medicinenet.com)
Multiple sclerosis (MS) is a degenerative disease in which the insulating covers called myelin sheaths, of nerve cells in the brain and spinal cord are damaged. (wikipedia.org)
Multiple sclerosis (MS) is a nervous system disease that affects your brain and spinal cord. (medlineplus.gov)
Relationships of brain white matter microstructure with clinical and MR measures in relapsing-remitting multiple sclerosis. (ox.ac.uk)
The term "multiple sclerosis" refers to the many areas of scarring (sclerosis) that result from destruction of the tissues that wrap around nerves (myelin sheath) in the brain and spinal cord. (msdmanuals.com)

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. (qxmd.com)

Anatomy19

Organisms4

Diseases40

Chemicals and Drugs25

Analytical, Diagnostic and Therapeutic Techniques and Equipment15

Psychiatry and Psychology2

Phenomena and Processes7

Information Science2

Named Groups1

Health Care9

RRMS13

Active relapsing remittin2

Patients32

Reducing relapse rate2

Aggressive relapsing-remittin1

Exacerbations2

Therapies6

Alemtuzumab1

Nerve Fibers2

Incidence of relapses2

Interferon Beta1

Expanded Disab2

Efficacy1

Fingolimod2

Clinical relapses1

Magnetic Resonan3

Symptoms6

EDSS2

Lesions8

Cohort2

Pathology4

Disability outcomes1

People with multiple sclerosis1

Cochrane1

Outcomes1

Compared with placebo1

Clinically2

Disease duration1

Frequency2

Treatment11

Disorders2

Experimental3

Autoimmune1

Immune-mediated2

Inflammatory4

Atrophy1

Pediatric1

20221

Mice1

Adults1

Trials1

20172

Brain6

Study1